NRG
DGX icon

Nemes Rush Group’s Quest Diagnostics DGX Stock Holding History

Nemes Rush Group’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.37K Hold
7
– – ﹤0.01% 789
2025
Q4 		$1.22K Hold
7
– – ﹤0.01% 790
2025
Q3 		$1.33K Hold
7
– – ﹤0.01% 618
2025
Q2 		$1.26K Hold
7
– – ﹤0.01% 635
2025
Q1 		$1.18K Hold
7
– – ﹤0.01% 641
2024
Q4 		$1.06K Buy
+7
New +$1.09K ﹤0.01% 660

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Nemes Rush Group's DGX Position: Q1 2026 in Review

Nemes Rush Group held its Quest Diagnostics (DGX) position steady in Q1 2026 at 7 shares worth $1.37K. The position accounts for ﹤0.01% of the portfolio, ranked #789.

Nemes Rush Group first reported a position in DGX in Q4 2024 and has held it in 6 quarters since. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Nemes Rush Group held 7 shares of Quest Diagnostics worth $1.37K as of Q1 2026.
  • Nemes Rush Group left its Quest Diagnostics share count unchanged in Q1 2026.
  • Quest Diagnostics made up ﹤0.01% of Nemes Rush Group's portfolio in Q1 2026, its #789 holding.
  • Nemes Rush Group first reported a position in Quest Diagnostics in Q4 2024 and has held it in 6 quarters since.
  • 1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.